| Zacks Company Profile for Sage Therapeutics, Inc. (SAGE : NSDQ) |
|
|
| |
| • Company Description |
| SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.
Number of Employees: 353 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $9.21 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 3,100,364 shares |
| Shares Outstanding: 62.62 (millions) |
| Market Capitalization: $576.74 (millions) |
| Beta: 0.29 |
| 52 Week High: $13.47 |
| 52 Week Low: $4.62 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
39.54% |
34.32% |
| 12 Week |
23.96% |
4.26% |
| Year To Date |
69.61% |
58.84% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
55 CAMBRIDGE PARKWAY
-
CAMBRIDGE,MA 02142
USA |
ph: 617-299-8380
fax: 617-299-8379 |
ir@sagerx.com |
http://www.sagerx.com |
|
|
| |
| • General Corporate Information |
Officers
Barry E. Greene - Chief Executive Officer; President and Director
Christopher Benecchi - Chief Operating Officer
Michael F. Cola - Director
James Frates - Director
Geno Germano - Director
|
|
Peer Information
Sage Therapeutics, Inc. (CORR.)
Sage Therapeutics, Inc. (RSPI)
Sage Therapeutics, Inc. (CGXP)
Sage Therapeutics, Inc. (BGEN)
Sage Therapeutics, Inc. (GTBP)
Sage Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 78667J108
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
|
|
Share - Related Items
Shares Outstanding: 62.62
Most Recent Split Date: (:1)
Beta: 0.29
Market Capitalization: $576.74 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.79 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-3.65 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 10.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 28.39% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/30/25 |
|
|
|
| |
